Answers are grounded in this paper and cite their sources.
Objective Circulating small RNAs, such as microRNAs (miRNAs) and transfer RNA fragments (tRFs), reportedly reflect the physiological and pathological conditions in various diseases. Herein, we aimed to identify circulating small RNAs for the early diagnosis of lung adenocarcinoma. Methods This study included 40 healthy controls and 43 patients with lung adenocarcinoma. We analyzed their serum using small RNA sequencing and identified differentially expressed small RNAs between healthy controls and patients with lung adenocarcinoma. We verified the expression profiles of these small RNAs in 29 patients with lung adenocarcinoma and 27 healthy controls. Finally, we evaluated our current results by performing machine learning-based analysis. Results The expressions of two mature miRNAs (miR-193a-5p, miR-423-5p), one miRNA isoform (isomiR) (miR-423-5p(21nt)), and two tRFs (tRF-Gly(CCC)(29nt), tRF-Gly(CCC)(30nt)) were significantly elevated in patients with lung adenocarcinoma than in healthy controls. Moreover, the expressions of one miRNA (miR-20a-5p) and five tRFs (tRF-iMet(CAT)(31nt), tRF-Lys(CTT), tRF-iMet(CAT)(30nt), tRF-iMet(CAT)(29nt), tRF-Val(AAC)) were significantly decreased in patients with lung adenocarcinoma than in healthy controls (area under the curve [AUC] values = 0.71 to 0.85, respectively). Furthermore, a combination of six small RNAs (miR-193a-5p, miR-423-5p(21nt), miR-20a-5p, tRF-Gly(CCC)(29nt), tRF-iMet(CAT)(29nt), and tRF-Val(AAC)) was useful for developing a biomarker panel for the early diagnosis of lung adenocarcinoma. Discovery screening revealed that the panel demonstrated a sensitivity of 0.954 and a specificity of 0.925 (AUC = 0.974), whereas the validation data demonstrated a sensitivity of 0.690 and a specificity of 0.926 (AUC = 0.924). Conclusion Serum-derived small RNAs are associated with the status of patients with lung adenocarcinoma, and evaluating small RNAs in serum is a promising non-invasive approach for diagnosing lung adenocarcinoma at an early stage.
No takes yet. Share an insight, caveat, or question.
Ueda et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: